2023
DOI: 10.1039/d3cc00663h
|View full text |Cite
|
Sign up to set email alerts
|

NAD(P)H: quinone oxidoreductase 1 activatable toll-like receptor 7/8 agonist designed for precise immunotherapy

Abstract: A NQO1-responsive precursor, named R848-QPA, has been developed for evoking anti-tumor immune response. This strategy can provide a new opinion for the development of tumor microenvironment-responsive prodrugs for antitumor immunotherapy.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
2

Relationship

1
1

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 22 publications
(29 reference statements)
0
1
0
Order By: Relevance
“…5). 71 The caged R848-QPA can achieve innate immune activation through intracellular overexpression of NQO1, while exhibiting reduced activity under conditions of NQO1-deprivation. After internalizing tumour cells, NQO1 induces the two-electron reduction of R848-QPA by forming an intramolecular cyclization lactone, resulting in the cleavage of the quinone trimethyl lock unit and subsequent release of R848 agonists.…”
Section: Design and Working Principles Of Small Molecule-based Tlr-7/...mentioning
confidence: 99%
“…5). 71 The caged R848-QPA can achieve innate immune activation through intracellular overexpression of NQO1, while exhibiting reduced activity under conditions of NQO1-deprivation. After internalizing tumour cells, NQO1 induces the two-electron reduction of R848-QPA by forming an intramolecular cyclization lactone, resulting in the cleavage of the quinone trimethyl lock unit and subsequent release of R848 agonists.…”
Section: Design and Working Principles Of Small Molecule-based Tlr-7/...mentioning
confidence: 99%